Every 10-Q that ResMed Inc. (RMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMD filings page.
ResMed Inc. delivered solid growth for the quarter ended March 31, 2026. Net revenue rose to $1.43 billion from $1.29 billion, driven mainly by higher demand and unit sales in its Sleep and Breathing Health segment and steady gains in Residential Care Software.
Net income increased to $398.7 million, with diluted EPS up to $2.74 from $2.48, supported by gross margin expansion to 62.2% from 59.3%. For the first nine months, revenue reached $4.19 billion and net income $1.14 billion, reflecting broad-based growth across regions and products.
Sleep and Breathing Health generated $1.26 billion in quarterly revenue, while Residential Care Software contributed $170.9 million. ResMed ended the quarter with $1.66 billion in cash and cash equivalents and total debt of about $664.1 million, after returning capital through dividends of $0.60 per share and share repurchases.
ResMed Inc. reported solid quarterly growth, with net revenue for the three months ended December 31, 2025 rising to $1.42 billion, up 11% from a year earlier (9% in constant currency). Sleep and Breathing Health products drove most of the increase, with devices and masks both seeing higher demand and unit sales across the U.S., Canada, Latin America, Europe, Asia and other markets.
Residential Care Software revenue grew 7% to $166.9 million, helped by strength in the MEDIFOX DAN and Home and Hospice verticals, partly offset by softer Senior Living and Long-Term Care performance. Company-wide gross margin improved to 61.8% from 58.6%, mainly due to manufacturing and logistics efficiencies and lower component costs.
Net income for the quarter grew to $392.6 million, with diluted earnings per share increasing to $2.68 from $2.34. For the first six months of the fiscal year, revenue reached $2.76 billion, up 10%, and gross margin rose to 61.6%. ResMed ended the period with $1.42 billion in cash and cash equivalents and $6.32 billion in stockholders’ equity, providing a sizable financial cushion alongside its global growth initiatives.
ResMed Inc. (RMD) reported stronger Q1 FY26 results. Net revenue was $1,335,582 thousand, up 9% year over year. Gross margin improved to 61.5% from 58.6%, reflecting manufacturing and component cost efficiencies. Net income was $348,536 thousand, with diluted EPS of $2.37 versus $2.11 a year ago.
Sleep and Breathing Health revenue reached $1,169,446 thousand (up 10%), driven by higher device and mask unit sales across the U.S., Canada and Latin America and in combined Europe, Asia and other markets. Residential Care Software delivered $166,136 thousand (up 6%), led by MEDIFOX DAN, partly offset by softer Senior Living and Long‑Term Care.
Operating cash flow was $457,321 thousand. Cash and cash equivalents were $1,383,848 thousand. The company repurchased $150,010 thousand of shares and declared a $0.60 per share dividend. Total debt was $668,560 thousand, with long-term debt down and short-term borrowings up. Restructuring expenses of $15,810 thousand were recorded for workforce planning. The Federal Circuit affirmed PTAB decisions invalidating NYU’s asserted patent claims, while certain Cleveland Medical PTAB reviews proceed with decisions expected by July 2026.